Neurent Medical

Neurent Medical is a MedTech company based in Galway, Ireland, with a U.S. office in Boston, MA. The company focuses on developing non-surgical treatments for chronic inflammatory sino-nasal diseases, particularly chronic rhinitis, which affects a significant portion of the population. Their flagship product, the NEUROMARK® System, offers a minimally invasive treatment using controlled low-power radiofrequency energy. This system targets and disrupts hyperactive autonomic nerves in the nasal cavity, addressing the underlying inflammation that causes chronic rhinitis symptoms. The NEUROMARK technology has received FDA 510(k) clearance and is supported by a Category I CPT reimbursement code, enhancing patient access to this innovative treatment. Additionally, it is endorsed by the American Academy of Otolaryngology–Head and Neck Surgery, underscoring its clinical value. Neurent Medical is backed by venture capital, including funding from Claret Capital Partners, and is committed to ongoing research and development to improve treatment outcomes and enhance patient quality of life.

• Employees 53
• Founded 2015
• Annual Revenue $3450000
• Total Funding $36319001